<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127252</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr 2021-03765</org_study_id>
    <nct_id>NCT05127252</nct_id>
  </id_info>
  <brief_title>Impact of the Microbiome on Time to Pregnancy and Pregnancy Outcomes in Fertile Women Attempting to Conceive</brief_title>
  <acronym>SweBioFertil</acronym>
  <official_title>Impact of the Microbiome on Time to Pregnancy and Pregnancy Outcomes in Fertile Women Attempting to Conceive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the microbiome of women with previously proven fertility who&#xD;
      plan to become pregnant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The women will be recruited at the time of removal of a copper or hormonal intrauterine&#xD;
      device (IUD) or removal of a contraceptive implant at the barnmorskemottagningar (midwife&#xD;
      clinics) in Stockholm's county in Sweden. A total of 500 women will be included in the study&#xD;
      and will be followed until conception or up to the end of 1 year, whichever comes first. If&#xD;
      conception occurs, the woman will be followed throughout pregnancy. Participant recruitment&#xD;
      will take place over a period of two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>The microbiome profile and metabolome associated with time to pregnancy, miscarriage, and live birth will be assessed.</measure>
    <time_frame>2024</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiome profiles and metabolome related to obstetric outcomes</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The microbiome profile for women above age &gt;38 and women below &lt;38.</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The influence of BMI, medications and comorbidities on the microbiome profiles.</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiome profile for those women who don't conceive within a year.</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The metabolome of the recognized microbiome for women with normal pregnancy outcomes</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The metabolome of the recognized microbiome for women who develop miscarriage or other pregnancy complications</measure>
    <time_frame>2024</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pregnancy Complications</condition>
  <condition>Contraception</condition>
  <condition>Pregnancy Loss</condition>
  <condition>Fertility</condition>
  <condition>Microbial Colonization</condition>
  <condition>Metabolome</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vaginal and rectal microbiome and metabolome</intervention_name>
    <description>Vaginal- and rectal sampling as a self-kit will be taken by the pat when ceasing the contraception at the midwife clinic when confirmed a clinical pregnancy and if a miscarriage occurs. If a miscarriage occurs additionally to the self-kit an endometrial biopsy will be taken.</description>
    <other_name>SweBioFertil</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The samples will be analyzed on the high-throughput pipeline for microbiome studies at CTMR&#xD;
      at KI. The pipeline includes standardized DNA extraction steps, library prep and shotgun&#xD;
      metagenomic sequencing on the MGI sequencers available at the centre. Dedicated bioinformatic&#xD;
      pipelines for taxonomy and functional capacity of the microbiome will be applied.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with previously proven fertility who plan to become pregnant. The women will be&#xD;
        recruited at the time of removal of a copper or hormonal intrauterine device (IUD) or&#xD;
        removal of a contraceptive implant&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with a previous live birth in the past 5 years and planning a new pregnancy with&#xD;
             the same male partner.&#xD;
&#xD;
          -  18-40 years of age&#xD;
&#xD;
          -  Swedish personal identity number and a Swedish address (to send a sampling self-kit)&#xD;
&#xD;
          -  Sufficient understanding of spoken and written Swedish or English to provide informed&#xD;
             consent and complete the web-based questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who do not have a child yet and plan to cease their contraception.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Holmgren, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lars Holmgren, Professor</last_name>
    <phone>046734036794</phone>
    <email>lars.holmgren@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Sebastian Brusell Gidl√∂f, PhD</last_name>
    <phone>08-517 700 00</phone>
    <email>sebastian.brusell-gidlof@regionstockholm.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproductive Medicine, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <state>Huddinge</state>
        <zip>141 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <investigator>
      <last_name>Kenny Rodriguez-Wallberg, Proff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Kenny Rodriguez-Wallberg</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>cohort</keyword>
  <keyword>fertility</keyword>
  <keyword>microbiome</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Pregnancy Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

